CERS vs LIN · rev $201.3M vs P/E 34, rev $33.99B
Cerus Corporation (CERS) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Cerus Corporation (CERS) is a medical devices company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported CERS revenue for 2024-12-31 was $201.3M. Net income was -$21.0M. Revenue was up 7.8% from 2023-12-31 to 2024-12-31. CERS currently screens at market cap $294.4M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
CERS currently screens at market cap $294.4M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the CERS and LIN stock pages for the full models.
Not investment advice.